ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Glenmark receives Orphan Drug Designation for GBR 1342 biospectrumasia
September 18, 2019Derived from the company’s proprietary BEAT? (Bispecific Engagement by Antibodies based on the T cell receptor) technology, GBR 1342 is being investigated for the treatment of multiple myeloma.
Pharma Sources Insight January 2025
